Axsome Therapeutics, Inc. (LON:0HKF)

Market Cap	5.31B
Revenue (ttm)	308.08M
Net Income (ttm)	-229.42M
Shares Out	n/a
EPS (ttm)	-4.79
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,403
Average Volume	1,864
Open	127.96
Previous Close	128.23
Day's Range	128.55 - 135.38
52-Week Range	55.64 - 135.38
Beta	n/a
RSI	74.02
Earnings Date	Feb 20, 2025

About Axsome Therapeutics

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also ...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2012
• Employees: 545
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0HKF

Financial Performance

In 2024, Axsome Therapeutics's revenue was $385.69 million, an increase of 42.53% compared to the previous year's $270.60 million. Losses were -$287.22 million, 20.1% more than in 2023.

Financial numbers in USD